All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What progress has been made with first-generation menin inhibitors in AML, and what needs remain?

By Sari Cumming

Share:

Featured:

Joshua ZeidnerJoshua Zeidner

Nov 16, 2026

Learning objective: After reading this article, learners will be able to summarize the clinical activity and limitations of first-generation menin inhibitors in R/R KMT2Ar or NPM1m AML, and describe emerging strategies to improve treatment outcomes.


Do you know... Which of the following best describes the current key clinical limitations of first-generation menin inhibitors in the treatment of AML?

The AML Hub was pleased to speak with Joshua Zeidner, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What progress has been made with first-generation menin inhibitors in AML, and what needs remain? 

What progress has been made with first-generation menin inhibitors in AML, and what needs remain?

During this interview, Zeidner discusses the clinical advances achieved with first-generation menin inhibitors, revumenib and ziftomenib, for patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) or NPM1-mutated (NPM1m) AML, and he highlights limited durations of response (DoRs) and acquired resistance as remaining unmet needs in this space. He also explores the potential of next-generation menin inhibitors, including bleximenib and enzomenib, and combination strategies to address the ongoing limitations. 

Key points

  • First-generation menin inhibitors represent a key advance in AML management, offering targeted treatment options for patients with R/R KMT2Ar or NPM1m AML. Both revumenib and ziftomenib have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of R/R NPM1m AML, while revumenib is also approved for patients with R/R KMT2Ar acute leukemia.1,2 
  • Although first-generation menin inhibitors have demonstrated promising clinical activity in patients with R/R acute leukemias, important unmet needs persist. 
    • In the phase II AUGMENT-101 trial (NCT04065399), revumenib monotherapy demonstrated an overall response rate (ORR) of 64% in patients with R/R KMT2Ar acute leukemia (efficacy population; n = 97), supporting its potential role as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median DoR, however, was ~6 months.3 
    • In patients with R/R NPM1m AML, a generally older patient population in whom allo-HSCT may not be a feasible treatment option, revumenib and ziftomenib have demonstrated ORRs of approximately 33–47% and median DoRs of ~5 months.4,5 
    • Therefore, key priorities for clinical research are to further improve ORRs and response durability, particularly in patients with R/R NPM1m AML. 
  • Acquired resistance is a clinical challenge, with the emergence of MEN1 mutations following menin inhibitor treatment potentially altering drug binding and contributing to loss of response.6,7 
  • Next-generation menin inhibitors, including enzomenib and bleximenib, are being investigated to build on the clinical activity of first-generation agents and address broader limitations of menin inhibitor treatment. Encouraging preliminary clinical activity has been reported, and preclinical and early clinical findings suggest that bleximenib may retain activity against certain MEN1 resistance mutations.8–10 
  • Combination strategies are also being investigated, including adding menin inhibitors to established treatment backbones such as hypomethylating agents (HMAs) plus venetoclax, or other targeted therapies such as FLT3 inhibitors, to increase response rates, leverage complementary mechanisms of action, and potentially address resistance.11–14 
  • First-generation menin inhibitors have introduced targeted treatment options for patients with KMT2Ar or NPM1m AML; however, improving response durability and addressing acquired resistance remain key priorities, with next-generation menin inhibitors and combination strategies offering potential approaches to address these unmet needs. 

This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. 

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

Where do you see the greatest future value for NGS-based MRD assessment in AML/MDS?